Would you like to participate in a research study for Hemophilia A?

We are inviting you to take part in a research study for adults diagnosed with Hemophilia A. There is no study medication, therapy, or experimental procedures. If you agree to participate, you will be asked to download a study specific Application (‘App’) to your smart-phone or device. The App will be used by you to participate in this study and to complete study specific questionnaires. You will also be asked to visit a local LabCorp Patient Service Center (PSC) of your choice to provide one blood sample on TWO (2) separate occasions. You will receive compensation for each blood sample collected and completion of questions in the form of a $50 gift card (max $100) for your time and participation.

The first sample will be collected at baseline (day 1) and the second will be collected either 12 weeks or 24 weeks later. No health insurance is required to participate.

This study has been approved by WIRB, an Independent Review Board (IRB).

The SAAVY (270-701) Study is analyzing blood samples from patients with Hemophilia A to look at how the body may develop antibodies against a certain type of virus called adeno-associated virus (AAV). The aim of the study is to also determine the occurrence of these antibodies in patients with Hemophilia A, to help develop therapies for patients with Hemophilia A.

You may qualify for the SAAVY (270-701) Study if:

  • You are over 18 years of age; and
  • You have a diagnosis of Hemophilia A
You will be eligible to receive a $50 gift card upon completion of each of your study visits and completing short questions via the App. There are two (2) separate visits for a blood sample during your participation.The maximum amount of compensation provided will be $100 [$50 for each blood sample collected].
Participate
Participate
Participate

Hear more about the value of this study from experts in the Hemophilia community

Sign Up

What happens if I sign up? If you think you might like to participate in the SAAVY (270-701) study or would like more information, please enter your information below to see if you qualify.


Keep in mind that participation is entirely voluntary. If you do decide to take part in a study, you may change your mind about participating at any time.

About the SAAVY (270-701) Study

The SAAVY – Seroprevalence of AAV AntibodY study is being conducted across the USA and will enroll up to approximately 1000 participants with Hemophilia A.

There is no cost to take part in the study, there is no study medication, therapy, or experimental procedures. If you agree to participate, you will be asked to download a study specific Application (‘App’) to your smart-phone or device. The App will be used by you to participate in this study and to complete study specific questionnaires. You will also be asked to provide one blood sample on two (2) separate occasions. The first sample will be collected at baseline (day 1) and the second will be collected either 12 weeks (3 months) or 24 weeks (6 months) later.

Volunteers who qualify to take part in the study will receive compensation in the form of a $50 gift card, (maximum $100) for their time in providing samples and completing the questions for each visit [$50 for each blood sample collected].

Who can take part in the SAAVY (270-701) study?

You may be able to take part in the study if:

  • You are over 18 years of age; and
  • You have a diagnosis of Hemophilia A

All study-related care is provided by a Specialist Medical Team.

The SAAVY (270-701) Study is analyzing blood samples from patients with Hemophilia A to look at if they already have antibodies against a certain type of naturally occurring virus called adeno-associated virus (AAV). Our aim is to also determine the occurrence of these antibodies, so we can better develop therapies for Hemophilia A.

For more information on the advantages of understanding the prevalence of AAV antibodies and how this information could be used in the development of future gene therapies, watch our expert interviews.

Advantage of understanding prevalence of AAV antibodies - https://youtu.be/YoRtdiwctPY

SAAVY study results and the development of gene therapies using AAV - https://youtu.be/yj9_DNCZ7bo

Frequently Asked Questions

What is the purpose of the SAAVY (270-701) study?

The purpose of this study is to analyze blood samples from patients with Hemophilia A and to look at how the body may develop antibodies against a certain type of virus called adeno-associated virus (AAV). AAVs are associated with a range of common illnesses (e.g. common colds) and some people naturally create antibodies to fight the virus.

Our aim is to also determine the occurrence of these antibodies so we can better develop therapies for Hemophilia A.

This study is a research study and there is no study medication, therapy, or experimental procedures.

  • If you agree to participate, you will be asked to download a study specific Application (‘App’) to your smart-phone or device. The App will be used by you to participate in this study and complete study specific questionnaires. A unique PIN will be provided to you to enter the App to participate.
  • After reading and providing your consent to participate (and meeting the study criteria), you will be asked to call the study hotline team to schedule your appointment at a LabCorp Patient Service Center (PSC) of your choice, to have your blood sample taken.
  • After this, you will be chosen at random (like the flip of a coin), to have your second blood sample taken again in either 12 weeks (3 months’) time, OR, 24 weeks (6 months’) time. You will call the study hotline team one additional time to schedule your appointment with the LabCorp Patient Service Center (PSC) for your second blood draw.

The study sponsor, BioMarin Pharmaceutical Inc., will use your samples for research purposes looking at antibodies to adeno-associated virus (AAV). All samples and data collected will not identify you by name and will not be provided to the sponsor. Further information can be found on the App in the information sheet during the consent process.

Duration of Study:
Your participation could last for up to 3 months or up to 6 months, depending on when you are asked to have your second blood draw.

You will be eligible for a $50 gift card upon completion of each of your study visits for blood sample collection, for a total of $100. Completion is defined as receipt of two (2) blood samples and completed questionnaires (all questions answered).

There is no cost to you to participate in the SAAVY (270-701) study. This study is a research study and there is no study medication, therapy, or experimental procedures.

Your participation in this study will be conducted via a mobile application and will include 2 visits to a LabCorp Patient Service Center (PSC) of your choice to have your blood samples taken.

The study team will be able to explain more about what the SAAVY (270-701) study will involve, and it is up to you to decide if you want to take part. Participation in this study is voluntary. Whether or not you decide to participate in this study, there will be no penalty to you and you can still get the same medical care as you could if you were not in this study. If you decide to participate, you are free to withdraw at any time.

During the study, you will twice visit a LabCorp Patient Service Center (PSC) in a location of your choice, to provide a blood sample. Other than those 2 times, your participation in this study will be conducted via a mobile application. You will be asked to download a study specific Application (‘App’) to your phone or device. The App will be used by you to register, consent and participate in this study and complete short study specific questionnaires.

About Hemophilia A

Hemophilia A is an inherited genetic bleeding disorder that is caused by a missing or defective clotting protein. This means the people who have Hemophilia A often experience heavy or longer bleeding than other people when they cut themselves or from trauma.1 Sometimes, these bleeds can be internal and occur in the joints and muscles.

Hemophilia affects more than 1.2 million individuals (mostly males), worldwide.2 Hemophilia almost always occurs in boys and men and is passed from mother to son through her genetics. Although women can be carriers, they usually do not have any symptoms.3

Because there are several clotting factors associated with Hemophilia A, the main treatment given to patients involves clotting-replacement therapy from donated blood, or from recombinant clotting factors that are manufactured.

The SAAVY (270-701) study is analyzing blood samples from patients with Hemophilia A to look at if they already have antibodies against a certain type of naturally occurring virus called adeno-associated virus (AAV). Our aim is to determine the occurrence of these antibodies, so we can better develop therapies for Hemophilia A, including gene therapies.

References: